Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma

Authors: Wei Dai, Quangen Gao, Jianping Qiu, Jianmao Yuan, Guoliang Wu, Genhai Shen

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Quercetin (Q), a flavonoid compound, which is obtained in variety of fruits, seeds, and vegetables, has been reported to possess many pharmacological properties including cancer-preventive and anticancer effects. However, studies on the anticancer effects and underlying mechanisms of Q in human hepatocellular carcinoma (HCC) are still limited. The present study is conducted to investigate the anticancer efficacy and adjuvant chemotherapy action of Q in HCC. HCC cell lines HepG2 and SMCC-7721 were treated with different concentrations of Q. The antiproliferative effects of Q were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the apoptosis and cell cycle dynamics were assessed by flow cytometry; the expression of apoptosis-associated proteins were evaluated by Western blot and immunohistochemistry staining; the tumor growth in vivo was evaluated in a xenograft mouse model. Our results showed that Q effectively inhibited human HCC cell proliferation and induced apoptosis by upregulating the expression of Bad and Bax and downregulating the expression of Bcl-2 and Survivin in vitro. Furthermore, Q obviously inhibited the tumor growth and enhanced the 5-fluorouracil (5-FU) therapeutic efficacy in vitro and in vivo. Taken together, our findings highlight that Q effectively inhibited the growth of tumor and enhanced the sensitivity to thermotherapy, indicating Q is a potential treatment option for HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I. Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J. 2011;8:496.CrossRefPubMedPubMedCentral Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I. Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J. 2011;8:496.CrossRefPubMedPubMedCentral
2.
go back to reference European Association For The Study Of The, L., R. European Organisation For, and C. Treatment Of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRef European Association For The Study Of The, L., R. European Organisation For, and C. Treatment Of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRef
3.
go back to reference European Association for Study of, L., R. European Organisation for, and C. Treatment of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.CrossRef European Association for Study of, L., R. European Organisation for, and C. Treatment of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.CrossRef
4.
go back to reference Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(05):330–8.CrossRefPubMed Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(05):330–8.CrossRefPubMed
5.
go back to reference Zhang C, Kolb A, Buchler P, Cato AC, Mattern J, Rittgen W, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer. 2006;6:61.CrossRefPubMedPubMedCentral Zhang C, Kolb A, Buchler P, Cato AC, Mattern J, Rittgen W, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer. 2006;6:61.CrossRefPubMedPubMedCentral
6.
go back to reference Lee SH, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, et al. Q enhances chemosensitivity to gemcitabine in lung cancer cells by inhibiting heat shock protein 70 expression. Clin Lung Cancer. 2015;16(6):e235–43.CrossRefPubMed Lee SH, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, et al. Q enhances chemosensitivity to gemcitabine in lung cancer cells by inhibiting heat shock protein 70 expression. Clin Lung Cancer. 2015;16(6):e235–43.CrossRefPubMed
7.
go back to reference Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low concentration of Q antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One. 2014;9(7):e100314.CrossRefPubMedPubMedCentral Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low concentration of Q antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One. 2014;9(7):e100314.CrossRefPubMedPubMedCentral
8.
go back to reference Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231–7.PubMed Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231–7.PubMed
9.
go back to reference Lee RH, Cho JH, Jeon YJ, Bang W, Cho JJ, et al. Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1). Drug Dev Res. 2015. Lee RH, Cho JH, Jeon YJ, Bang W, Cho JJ, et al. Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1). Drug Dev Res. 2015.
10.
go back to reference Sudan S, Rupasinghe HV. Antiproliferative activity of long chain acylated esters of Q-3-O-glucoside in hepatocellular carcinoma HepG2 cells. Exp Biol Med (Maywood). 2015;240(11):1452–64.CrossRef Sudan S, Rupasinghe HV. Antiproliferative activity of long chain acylated esters of Q-3-O-glucoside in hepatocellular carcinoma HepG2 cells. Exp Biol Med (Maywood). 2015;240(11):1452–64.CrossRef
11.
go back to reference Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000–5.CrossRefPubMed Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000–5.CrossRefPubMed
12.
go back to reference Richardson A, Kaye SB. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008;1(3):244–54.CrossRefPubMed Richardson A, Kaye SB. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008;1(3):244–54.CrossRefPubMed
13.
go back to reference Smith DM, Gao G, Zhang X, Wang G, Dou QP. Regulation of tumor cell apoptotic sensitivity during the cell cycle (review). Int J Mol Med. 2000;6(5):503–7.PubMed Smith DM, Gao G, Zhang X, Wang G, Dou QP. Regulation of tumor cell apoptotic sensitivity during the cell cycle (review). Int J Mol Med. 2000;6(5):503–7.PubMed
14.
go back to reference Bajwa N, Liao C, Nikolovska-Coleska Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat. 2012;22(1):37–55.CrossRefPubMed Bajwa N, Liao C, Nikolovska-Coleska Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat. 2012;22(1):37–55.CrossRefPubMed
15.
go back to reference Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20(12):1723–37.CrossRefPubMed Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20(12):1723–37.CrossRefPubMed
16.
go back to reference Golbano JM, Loppez-Aparicio P, Recio MN, Perez-Albarsanz MA. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008;32(4):919–24.PubMed Golbano JM, Loppez-Aparicio P, Recio MN, Perez-Albarsanz MA. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008;32(4):919–24.PubMed
17.
go back to reference Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17(14):3878–85.CrossRefPubMedPubMedCentral Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17(14):3878–85.CrossRefPubMedPubMedCentral
18.
go back to reference Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res. 2002;8(2):607–14.PubMed Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res. 2002;8(2):607–14.PubMed
19.
go back to reference Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 2007;7:4.CrossRefPubMed Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 2007;7:4.CrossRefPubMed
20.
go back to reference Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P, et al. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. Oncotarget. 2015;6(13):11547–60.CrossRefPubMedPubMedCentral Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P, et al. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. Oncotarget. 2015;6(13):11547–60.CrossRefPubMedPubMedCentral
Metadata
Title
Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma
Authors
Wei Dai
Quangen Gao
Jianping Qiu
Jianmao Yuan
Guoliang Wu
Genhai Shen
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4501-0

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine